Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

G7 urged to donate 'emergency' supplies to vaccine-sharing scheme

Published 05/16/2021, 08:04 PM
Updated 05/17/2021, 06:21 AM
© Reuters. FILE PHOTO: Vials labelled "AstraZeneca, Pfizer - Biontech, Johnson&Johnson, Sputnik V coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic/Illustration//File Photo

By Emma Farge

GENEVA (Reuters) - The head of UNICEF on Monday asked G7 countries to donate supplies to the COVAX vaccine-sharing scheme as an emergency measure to address a severe shortfall caused by disruption to Indian vaccine exports.

India has curbed exports of the AstraZeneca (NASDAQ:AZN) vaccine made by its Serum Institute, which had been pledged to COVAX, to be used by the country as it battles a massive second wave of infections.

U.N. agency UNICEF, which is in charge of supplying coronavirus vaccines through COVAX, estimates the supply shortfall at 140 million doses by the end of May and about 190 million by the end of June.

"Sharing immediately available excess doses is a minimum, essential and emergency stop-gap measure, and it is needed right now," said UNICEF Executive Director Henrietta Fore, adding that this could help to prevent vulnerable countries from becoming the next global hotspot.

As G7 leaders prepare to meet in Britain next month, the head of the World Health Organization last week denounced the "moral catastrophe" of vaccine inequity, urging wealthy countries to donate doses rather than use them for children who are less vulnerable to severe disease.

Citing new research from scientific information and analytics company Airfinity, UNICEF's Fore said that G7 countries could donate about 153 million doses if they shared only 20% of their available supply over June, July and August.

This could be done while still meeting commitments to vaccinate their own populations, she said without providing further detail.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

COVAX, run jointly by the WHO and the GAVI vaccine alliance, relies heavily on the AstraZeneca shot, which accounts for the bulk of the vaccines earmarked for early rollout as it seeks to provide 2 billion doses this year.

UNICEF said that other manufacturing limitations outside India had also slowed supply of COVAX doses but those delays are expected to be resolved by the end of June.

Latest comments

scheme. nice
In other words: usa should pay for all vaccines
A commendable initiative
Except nobody gives away free. Usa will but the world will be thankless n stll full of h/a/ting usa
Don’t take the warp speed experimental “vaccine” the side effects 5 years from now will be terrible and you can’t even sue the pharmaceutical companies.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.